Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Junshi Biosciences Co., Ltd.

http://junshipharma.com/en/Index.html

Latest From Shanghai Junshi Biosciences Co., Ltd.

Shionogi Files Antiviral NDA In China, Eyes Wider Use

Undeterred by recent home turf setback, Japanese drug maker Shionogi rides a China’s policy tailwind and bets on Chinese approval for its antiviral COVID drug.

Coronavirus COVID-19 China

BeiGene Latest Chinese Biotech To Double Down On mRNA For Cancer

Chinese biotechs have reached deals for cancer therapies to explore the novel uses of messenger RNA technology beyond COVID-19 vaccines, as the mRNA COVID-19 vaccine fame starts fading.

Commercial China

CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global

While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.

Research & Development China

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.

Vaccines M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Junshi Biosciences
UsernamePublicRestriction

Register